Danish Pharma Stock News

NKT (CPSE:NKT) has secured its largest single cable contract, a firm agreement worth more than €2.2b for the Eastern Green Link 3 HVDC project in the UK. This deal expands the company’s high voltage order backlog. See our latest analysis for NKT. NKT’s EGL3 contract and recent decision to refinance its subordinated capital securities come against a backdrop of firm share price momentum, with a 1 day share price return of 3.3%, a 7 day share price return of 8.4%, and a 1 year total shareholder...

Share buy-back puts Alm. Brand (CPSE:ALMB) in focus Alm. Brand (CPSE:ALMB) has drawn fresh investor attention after announcing a share buy-back program of up to DKK 835.2 million, with the company now holding 3.44% of its own shares. See our latest analysis for Alm. Brand. At a share price of DKK16.34, Alm. Brand has seen a 1-day share price return of 1.24% and a 7-day share price return of 2.57%, although the 30-day and year-to-date share price returns of 4.28% and 12.15% declines suggest...

If you are wondering whether Danske Bank shares still offer value after a strong run, this article walks through what the current price might be implying about the company. The stock last closed at DKK 325.30, with returns of 2.7% over 7 days, a 4.4% decline over 30 days, 1.8% year to date and 48.2% over 1 year, while the 3 year and 5 year returns stand at 169.7% and 239.3% respectively. Recent headlines around Danske Bank have focused on its position among Nordic lenders and how investors...

Novo Nordisk (CPSE:NOVO B) has resolved its legal dispute with Hims & Hers Health over compounded GLP-1 weight loss treatments. The two companies have entered a new commercial partnership for Hims & Hers to distribute Novo Nordisk's branded weight loss drugs, including Ozempic and Wegovy, via its telehealth platform. As part of the agreement, Hims & Hers will stop promoting compounded GLP-1 products, focusing instead on Novo Nordisk's FDA approved therapies. Novo Nordisk, known for its...

How Novozymes Shares Have Been Performing Novozymes (CPSE:NSIS B) has been under pressure recently, with the stock showing a 2.3% decline over the past day and deeper pullbacks over the past week, month, and past 3 months. Over the past year, Novozymes has delivered a total return of 9.6%. The year to date move reflects a 10.5% decline. Looking at longer periods, the 3 year total return stands at 11.9%, and the 5 year total return shows a 4.0% decline. See our latest analysis for...

CEO change puts fresh focus on Coloplast shares Coloplast (CPSE:COLO B) is back in focus after the board named Gavin Wood as President and CEO, effective May 1, 2026, following a period under interim chief Lars Rasmussen. See our latest analysis for Coloplast. The CEO announcement comes after a weaker run for the shares, with a 7 day share price return of 7.04% and a 90 day share price return of 20.51%. This has contributed to a 1 year total shareholder return of 37.52% and a 5 year total...

A.P. Møller - Mærsk recently suspended key container services linking the Middle East with Europe and Asia, along with Gulf shuttle operations, and altered its ME1 rotation to bypass Jebel Ali as it responds to heightened security risks in the region. This shift reroutes cargo away from a major Middle Eastern hub, potentially reshaping how global shippers manage transit times, capacity, and supply chain resilience across these trade lanes. We’ll now examine how this temporary suspension of...

Aktieselskabet Schouw (CPSE:SCHO) just reported full year 2025 results, pairing lower net income with a higher proposed dividend and strong cash flow. This combination gives you several angles to assess the stock. See our latest analysis for Aktieselskabet Schouw. These results land after a weak run in the share price, with a 7 day share price return of 7.60% and a 30 day share price return of 10.40%. However, the 1 year total shareholder return of 4.31% and 3 year total shareholder return of...

Zealand Pharma (CPSE:ZEAL) is under close watch after Phase 2 topline data for obesity drug candidate petrelintide triggered a sharp share price drop, despite meeting the trial’s primary weight loss and safety goals. See our latest analysis for Zealand Pharma. The sharp 1 day share price return of 36.4% and 7 day share price return of 36.1% have reversed much of Zealand Pharma’s earlier gains. However, the 3 year total shareholder return of 4.9% and 5 year total shareholder return of 23.7%...

Earnings jump puts UIE (CPSE:UIE) in focus UIE (CPSE:UIE) is back on the radar after reporting full year 2025 earnings, with sales of US$587.28 million and net income of US$139.92 million, alongside basic EPS of US$4.48 from continuing operations. See our latest analysis for UIE. The earnings release comes after a mixed period for the shares, with a 1-day share price return of 0.98% and 7-day share price return of 0.84%. This is set against a 30-day share price return of 4.50% and year to...

If you are wondering whether Aktieselskabet Schouw is attractively priced right now, the starting point is to separate what the share price is doing from what the underlying value might suggest. The stock last closed at DKK 634.0, with returns of a 6.4% decline over 7 days, a 6.1% decline over 30 days, a 4.5% decline year to date, and a 5.8% gain over 1 year, a 20.5% gain over 3 years, and a 10.1% gain over 5 years. Taken together, this gives you a mixed picture of recent sentiment over...

Maersk, ticker CPSE:MAERSK B, has temporarily suspended multiple key shipping routes to and from the Middle East. The halt affects links between the Middle East and Europe as well as Asia, in response to escalating conflict and security concerns. These adjustments touch several major services and ports that form part of Maersk’s global container network. A.P. Møller – Mærsk is one of the world’s largest container shipping and logistics groups, so route suspensions of this scale can matter...

Zealand Pharma reported positive Phase 2 topline results for petrelintide, its obesity drug candidate, with clinically meaningful weight loss and strong tolerability. The trial met its primary weight reduction endpoint and showed a favorable safety profile, according to the company. The news has arrived as investors reassess Zealand Pharma’s position in the obesity drug space and its collaboration with Roche. For holders of CPSE:ZEAL, the latest petrelintide data lands after a sharp reset...

Scandinavian Tobacco Group (CPSE:STG) has wrapped up FY 2025 with fourth quarter revenue of DKK 2,343.3 million and basic EPS of DKK 2.10, set against trailing 12 month revenue of DKK 9,035.7 million and EPS of DKK 8.5. Over recent quarters the company has seen revenue move from DKK 2,457.5 million in Q4 2024 to between DKK 2,361.4 million and DKK 1,973.7 million through the first three quarters of 2025. Quarterly EPS ranged from DKK 0.7 to DKK 2.9, leaving investors focused on how the latest...

Netcompany Group (CPSE:NETC) is back in focus after its fully electronic Annual General Meeting on 5 March 2026, where shareholders approved a share capital reduction, no dividend for 2025, and amendments to the Articles of Association. See our latest analysis for Netcompany Group. Those AGM decisions come as the share price sits at DKK337.4, with a 1 day share price return of 1.69% and a 7 day share price return of 4.39%. The 1 year total shareholder return of 14.45% contrasts with a 5 year...

Bavarian Nordic CEO Paul Chaplin is set to step down after a period of transformational leadership. The leadership change follows a recently failed acquisition bid that had aimed to reshape the company. The transition comes alongside turnover at the chairman level, marking a broad shift at the top of the organization. Bavarian Nordic, traded as CPSE:BAVA, enters this leadership transition with its shares at DKK187.6. The stock is up 12.0% over the past year, but shows declines of 4.7% over...

If you are wondering whether Novo Nordisk’s current share price reflects its true value, this article walks through what the numbers are really saying about the stock. The shares last closed at DKK 248.65, with returns of 4.2% over the past 7 days, a 32.4% decline over 30 days, a 24.7% decline year to date, a 58.2% decline over 1 year and a 48.1% decline over 3 years, while the 5 year return stands at 21.6%. Recent coverage around Novo Nordisk has continued to focus on its role in the global...

In recent days, DSV reported that the Middle East conflict and a blockade of the Strait of Hormuz have severely disrupted vessel movements, forcing rerouting and causing potential delays across multiple shipping services. The company has activated contingency plans to protect capacity, diversify carrier options, and offer flexible routing, underlining how operational resilience is now central to its logistics proposition. We’ll now examine how DSV’s contingency response to Strait of Hormuz...

TORM (CPSE:TRMD A) has called its 2026 Annual General Meeting for 15 April in London, where shareholders will vote on authorizing sizeable off-market share buyback contracts that could influence future capital allocation. See our latest analysis for TORM. The AGM notice arrives after a busy period for TORM, including full year 2025 results, updated 2026 TCE guidance and a new interim dividend. It also comes at a time when the share price is DKK185.2 with a 30 day share price return of 19.25%,...

If you are wondering whether Carlsberg is fairly priced at its current level, this article will walk you through what the numbers say about its value and what that could mean for you. Carlsberg shares last closed at DKK 914.80, with returns of 7% decline over the past week, 3.6% over the past month, 10.8% year to date, 4.9% over one year, 2.3% decline over three years and 4.1% over five years. This gives a mixed picture of recent performance and risk perception. Recent news coverage around...

NTG Nordic Transport Group (CPSE:NTG) has wrapped up FY 2025 with fourth quarter revenue of DKK2.9b and basic EPS of DKK3.69, while trailing twelve month revenue landed at DKK11.4b alongside EPS of DKK9.93. Over the past six quarters, the company has seen quarterly revenue range between DKK2.3b and DKK3.0b, with basic EPS moving from DKK2.16 in Q3 2024 to DKK3.69 in Q4 2025 as margins came under pressure. With net profit margins easing from 3.6% to 1.9% over the last year, the latest numbers...

Earnings, buyback and guidance put AL Sydbank (CPSE:ALSYDB) in focus AL Sydbank (CPSE:ALSYDB) is back on investors' radar after full year 2025 earnings, fresh 2026 profit guidance and a sizeable share repurchase program tied to a capital structure adjustment plan. See our latest analysis for AL Sydbank. Despite full year 2025 results, new 2026 profit guidance and the DKK 1,100m buyback plan putting AL Sydbank in the spotlight, the 1 month share price return is a 6.14% decline. In contrast,...

H+H International (CPSE:HH) has wrapped up FY 2025 with Q4 revenue of DKK 611 million and a basic EPS loss of DKK 1.48. The trailing twelve months show total revenue of DKK 2,743 million against a net loss of DKK 662 million and basic EPS of DKK 40.3 in the red. Over the past six reported quarters, revenue has moved within a relatively tight band between DKK 649 million and DKK 738 million per quarter. However, EPS has swung from a profit of around DKK 5.80 in Q4 2024 to a deep quarterly loss...

If you are wondering whether A.P. Møller - Mærsk is reasonably priced or starting to look stretched, you are asking the right question before making any long term decisions. The stock recently closed at DKK 17,020, with returns of 11.0% over 7 days, 7.2% over 30 days, 15.9% year to date, 53.7% over 1 year, 75.4% over 3 years and 135.2% over 5 years. This naturally puts extra attention on what you are paying today. Recent headlines around A.P. Møller - Mærsk have largely focused on shipping...